Connor, Clark & Lunn Investment Management Ltd. Biotechnology

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$99.5B	$91.8 Million 0.35% of portfolio	206,095	Q2 2025 Added 1,251.18%
BGNE Bei Gene, Ltd.	$23.5B	$68.7 Million 0.26% of portfolio	302,999	Q2 2025 Added 3.91%
INCY Incyte Corp	$18.2B	$31.2 Million 0.12% of portfolio	458,256	Q2 2025 Reduced 14.14%
MDGL Madrigal Pharmaceuticals, Inc.	$6.14B	$30.3 Million 0.12% of portfolio	100,095	Q2 2025 Reduced 2.21%
AXSM Axsome Therapeutics, Inc.	$4.51B	$23.5 Million 0.09% of portfolio	224,721	Q2 2025 Added 27.72%
CORT Corcept Therapeutics Inc	$7.88B	$23.3 Million 0.09% of portfolio	318,005	Q2 2025 Reduced 57.67%
INSM Insmed Inc	$16.5B	$22.8 Million 0.09% of portfolio	226,142	Q2 2025 Added 1,393.38%
BMRN Biomarin Pharmaceutical Inc	$10.6B	$22.2 Million 0.09% of portfolio	403,547	Q2 2025 Reduced 22.6%
MIRM Mirum Pharmaceuticals, Inc.	$2.38B	$21.6 Million 0.08% of portfolio	423,744	Q2 2025 Added 18.94%
UTHR United Therapeutics Corp	$13.7B	$17.2 Million 0.07% of portfolio	59,807	Q2 2025 Added 177.01%
AGIO Agios Pharmaceuticals, Inc.	$1.94B	$16.8 Million 0.06% of portfolio	505,225	Q2 2025 Added 30.71%
JAZZ Jazz Pharmaceuticals PLC	$7.1B	$15 Million 0.06% of portfolio	140,972	Q2 2025 Added 6.46%
ACAD Acadia Pharmaceuticals Inc	$4.12B	$13.9 Million 0.05% of portfolio	642,448	Q2 2025 Added 12.26%
ZLAB Zai Lab LTD	$3.36B	$13.5 Million 0.05% of portfolio	387,362	Q2 2025 Reduced 61.61%
IMVT Immunovant, Inc.	$3.55B	$12.3 Million 0.05% of portfolio	448,515	Q2 2025 Added 23.14%
VKTX Viking Therapeutics, Inc.	$3.06B	$11.9 Million 0.05% of portfolio	447,217	Q2 2025 Reduced 25.15%
BCRX Biocryst Pharmaceuticals Inc	$1.55B	$11.3 Million 0.04% of portfolio	1,257,691	Q2 2025 Added 20.65%
FOLD Amicus Therapeutics, Inc.	$1.96B	$10.5 Million 0.04% of portfolio	1,839,249	Q2 2025 Added 133.93%
SRPT Sarepta Therapeutics, Inc.	$1.6B	$10.5 Million 0.04% of portfolio	615,441	Q2 2025 Added 151.44%
IONS Ionis Pharmaceuticals Inc	$5.85B	$10.5 Million 0.04% of portfolio	265,793	Q2 2025 Added 105.61%
TVTX Travere Therapeutics, Inc.	$1.12B	$10.1 Million 0.04% of portfolio	685,511	Q2 2025 Added 38.44%
HRMY Harmony Biosciences Holdings, Inc.	$2.1B	$7.86 Million 0.03% of portfolio	248,859	Q2 2025 Added 117.9%
VCYT Veracyte, Inc.	$2.06B	$7.55 Million 0.03% of portfolio	279,188	Q2 2025 Added 19.21%
AMLX Amylyx Pharmaceuticals, Inc.	$481M	$7.4 Million 0.03% of portfolio	1,154,485	Q2 2025 Reduced 3.77%
RYTM Rhythm Pharmaceuticals, Inc.	$5.51B	$7.27 Million 0.03% of portfolio	115,118	Q2 2025 Added 127.7%
XERS Xeris Biopharma Holdings, Inc.	$992M	$5.73 Million 0.02% of portfolio	1,227,959	Q2 2025 Added 108.32%
AUPH Aurinia Pharmaceuticals Inc.	$1.61B	$5.51 Million 0.02% of portfolio	650,191	Q2 2025 Reduced 12.87%
MNKD Mannkind Corp	$942M	$5.12 Million 0.02% of portfolio	1,369,671	Q2 2025 Reduced 22.83%
CDXC Chroma Dex Corp.	$420M	$5.06 Million 0.02% of portfolio	823,325	Q2 2025 Added 10.59%
AKBA Akebia Therapeutics, Inc.	$610M	$4.3 Million 0.02% of portfolio	1,180,759	Q2 2025 Added 21.75%
VNDA Vanda Pharmaceuticals Inc.	$244M	$4.1 Million 0.02% of portfolio	868,419	Q2 2025 Reduced 6.59%
KROS Keros Therapeutics, Inc.	$353M	$3.55 Million 0.01% of portfolio	265,707	Q2 2025 Added 107.42%
ETON Eton Pharmaceuticals, Inc.	$438M	$3.16 Million 0.01% of portfolio	222,083	Q2 2025 Reduced 4.49%
PBYI Puma Biotechnology, Inc.	$222M	$3.09 Million 0.01% of portfolio	900,256	Q2 2025 Added 8.24%
TARS Tarsus Pharmaceuticals, Inc.	$1.37B	$2.45 Million 0.01% of portfolio	60,495	Q2 2025 New
FULC Fulcrum Therapeutics, Inc.	$340M	$2.36 Million 0.01% of portfolio	342,547	Q2 2025 Added 57.31%
AKRO Akero Therapeutics, Inc.	$2.23B	$2.21 Million 0.01% of portfolio	41,328	Q2 2025 New
EXEL Exelixis, Inc.	$12.1B	$2.18 Million 0.01% of portfolio	49,520	Q2 2025 New
CPRX Catalyst Pharmaceuticals, Inc.	$2.09B	$2.06 Million 0.01% of portfolio	95,005	Q2 2025 Reduced 41.09%
APLS Apellis Pharmaceuticals, Inc.	$2.63B	$2.06 Million 0.01% of portfolio	118,724	Q2 2025 Reduced 9.99%
VTYX Ventyx Biosciences, Inc.	$149M	$2.02 Million 0.01% of portfolio	945,206	Q2 2025 Added 8.44%
INVA Innoviva, Inc.	$1.4B	$1.59 Million 0.01% of portfolio	78,903	Q2 2025 New
NVO Novo Nordisk A S	$112B	$1.4 Million 0.01% of portfolio	20,321	Q2 2025 Reduced 14.83%
RVMD Revolution Medicines, Inc.	$3.09B	$1.2 Million 0.0% of portfolio	32,695	Q2 2025 Reduced 81.81%
MDXG Mimedx Group, Inc.	$821M	$880,000 0.0% of portfolio	144,166	Q2 2025 Added 6.09%
MGNX Macrogenics Inc	$90.3M	$825,000 0.0% of portfolio	682,277	Q2 2025 Reduced 16.39%
PLX Protalix Bio Therapeutics, Inc.	$81.6M	$734,000 0.0% of portfolio	496,216	Q2 2025 Added 2.76%
SVRA Savara Inc	$294M	$706,000 0.0% of portfolio	309,835	Q2 2025 Reduced 60.22%
ARVN Arvinas, Inc.	$361M	$634,000 0.0% of portfolio	86,203	Q2 2025 New
RPRX Royalty Pharma PLC	$15.7B	$625,000 0.0% of portfolio	17,366	Q2 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.